Moderna's Data From Personalized Cancer Vaccine Provides Relief To Investors, Analyst Says

  • Moderna Inc MRNA and Merck & Co Inc's MRK investigational personalized mRNA cancer vaccine + Keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival versus Keytruda.
  • SVB Leerink has raised the price target on Moderna from $101 to $102.
  • The analyst says it has fielded a steady stream of inbounds from investors nervous about elevated expectations for personalized cancer vaccine (PCV) data and expects shares to trade up on relief in response to this data. 
  • The analyst expects the applicability of PCV outside of this setting to drive controversy as investors debate how directly one can translate data in Melanoma to other indications.
  • Oppenheimer keeps Neutral rating on Moderna. The analyst says that China's sales could be a near-term tailwind, but competition and pricing pressure could put downward pressure on MRNA's mid/long-term margins.
  • The analyst also writes that any order from China of mRNA vaccines for the 2023/24 fall season might take a few more months to formalize. 
  • Price Action: MRNA shares are up 23.60% at $204.18 on the last check Tuesday
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLarge CapNewsHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!